839708-52-0

Basic information

• Product Name: N-(3-(7-chloro-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-d]-pyrimidin-3(2H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide
• Synonyms: N-(3-(7-chloro-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-d]-pyrimidin-3(2H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide
• CAS NO: 839708-52-0
• Molecular Weight: 475.857
• Mol File: 839708-52-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(3-(7-chloro-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-d]-pyrimidin-3(2H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-(7-chloro-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-d]-pyrimidin-3(2H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(839708-52-0)
• EPA Substance Registry System: N-(3-(7-chloro-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-d]-pyrimidin-3(2H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide(839708-52-0)

Safety Data

• Hazardous Substances Data: 839708-52-0(Hazardous Substances Data)

Upstream product

• 839708-51-9 N-{3-[(2-chloro-4-methylaminopyrimidin-5-ylmethyl)amino]-4-methylphenyl}-3-trifluoromethylbenzamide 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 7627-38-5 2,4-dichloro-5-(chloromethyl)pyrimidine 
• 4433-40-3 5-(hydroxymethyl)pyrimidine-2,4-diol 
• 205672-24-8 5-bromo-2-chloro-N-methyl-pyrimidin-4-amine 
• 839708-49-5 (2-chloro-5-vinylpyrimidin-4-yl)methylamine 
• 839708-50-8 2-chloro-4-(methylamino)pyrimidine-5-carbaldehyde 
• 2251-65-2 3-(Trifluoromethyl)benzoyl chloride 

Downstream Products

• 839706-07-9 GNF-7 
• 839708-13-3 GNF-8 
• 839708-29-1 GNF-6 
• 839707-37-8 N-(3-(7-((1,3-dimethyl-1H-pyrazol-5-yl)amino)-1-methyl-2-oxo-1,4-dihydropyrimido[4,5-d]pyrimidin-3(2H)-yl)-4-methylphenyl)-3-(trifluoromethyl)benzamide 

Relevant articles and documents

First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia

GNF-7, a multitargeted kinase inhibitor, served as a dual kinase inhibitor of ACK1 and GCK, which provided a novel therapeutic strategy for overriding AML expressing NRAS mutation. This SAR study with GNF-7 derivatives, designed to target NRAS mutant-driven AML, led to identification of the extremely potent inhibitors, 10d, 10g, and 11i, which possess single-digit nanomolar inhibitory activity against both ACK1 and GCK. These substances strongly suppress proliferation of mutant NRAS expressing AML cells via apoptosis and AKT/mTOR signaling blockade. Compound 11i is superior to GNF-7 in terms of kinase inhibitory activity, cellular activity, and differential cytotoxicity. Moreover, 10k possessing a favorable mouse pharmacokinetic profile prolonged life-span of Ba/F3-NRAS-G12D injected mice and significantly delayed tumor growth of OCI-AML3 xenograft model without causing the prominent level of toxicity found with GNF-7. Taken together, this study provides insight into the design of novel ACK1 and GCK dual inhibitors for overriding NRAS mutant-driven AML.

COMPOUNDS THAT MAINTAIN PLURIPOTENCY OF EMBRYONIC STEM CELLS

The present invention relates to methods and compositions for culturing embryonic stem (ES) cells. The methods relate to growing the ES cells in the presence of small molecules of formula (I) that maintain the pluripotency/self-renewal of the cells withou